Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

17.10
-1.2700-6.91%
Volume:463.64K
Turnover:7.97M
Market Cap:2.90B
PE:-6.54
High:17.74
Open:17.73
Low:16.90
Close:18.37
Loading ...

Company Profile

Company Name:
Immunovant, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
207
Office Location:
320 West 37th Street,6th Floor,New York,New York,United States
Zip Code:
10018
Fax:
- -
Introduction:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Directors

Name
Position
Peter Salzmann
Chief Executive Officer,Director
Frank M. Torti
Director,Executive Chairperson of the Board
Andrew Fromkin
Director
Atul Pande
Director
Douglas Hughes
Director
Eric Venker
Director
George Migausky
Director

Shareholders

Name
Position
Peter Salzmann
Chief Executive Officer,Director
Eva Renee Barnett
Chief Financial Officer
Jay S. Stout
Chief Technology Officer
Julia G. Butchko
Chief Development Officer
Mark S. Levine
Chief Legal Officer and Corporate Secretary
William L. Macias
Chief Medical Officer